PMID- 19303802
OWN - NLM
STAT- MEDLINE
DCOM- 20090716
LR  - 20200205
IS  - 1778-7254 (Electronic)
IS  - 1297-319X (Linking)
VI  - 76
IP  - 3
DP  - 2009 May
TI  - Prevalence of subclinical amyloidosis in Tunisian patients with rheumatoid 
      arthritis.
PG  - 254-9
LID - 10.1016/j.jbspin.2008.08.009 [doi]
AB  - INTRODUCTION: Secondary amyloidosis is a serious complication of rheumatoid 
      arthritis (RA). Symptoms are late to occur, so that screening is in order, most 
      notably in patients with long-standing RA. The objectives of our study were to 
      determine the prevalence of subclinical amyloidosis in RA patients by abdominal 
      fat aspiration biopsy (AFAB) and minor salivary gland biopsy (MSGB) and to 
      identify factors associated with subclinical amyloidosis. METHODS: We 
      prospectively studied 107 consecutive patients with RA (94 women and 13 men) 
      recruited between March 2005 and January 2006. Clinical and laboratory findings, 
      imaging study results, and treatment were recorded for each patient. AFAB and 
      MSGB were performed routinely. Amyloid deposits were identified by polarized 
      light microscopy after Congo red staining. RESULTS: The prevalence of subclinical 
      amyloidosis was 21.5% by AFAB and 3.7% by MSGB. Factors associated with 
      subclinical amyloidosis were a longer time to diagnosis (P=0.03), extraarticular 
      manifestations (P=0.019), proteinuria >0.3 g/24 h (P=0.024), and absence of 
      methotrexate therapy (P=0.046). Subclinical amyloidosis was not associated with 
      age, sex, RA duration, joint deformities, DAS28 score, Health Assessment 
      Questionnaire score, Steinbrocker radiological stage, rheumatoid factor, 
      erythrocyte sedimentation rate, C-reactive protein, creatinine, or hemoglobin. 
      CONCLUSION: The prevalence of subclinical amyloidosis by AFAB is high (21.5%). 
      AFAB is more sensitive than MSGB for detecting subclinical amyloidosis. A simple 
      screening tool such as AFAB should be used, particularly in patients with risk 
      factors. Subclinical amyloidosis requires close monitoring to ensure the early 
      detection and treatment of symptomatic amyloidosis.
FAU - Younes, Mohamed
AU  - Younes M
AD  - Service de Rhumatologie-Hopital Universitaire Fattouma Bourguiba, avenue 1 juin, 
      Monastir 5000, Tunisia. mohamed_youn@yahoo.fr
FAU - Korbaa, Wided
AU  - Korbaa W
FAU - Moussa, Adnene
AU  - Moussa A
FAU - Zrour, Saoussen
AU  - Zrour S
FAU - Bejia, Ismail
AU  - Bejia I
FAU - Touzi, Mongi
AU  - Touzi M
FAU - Zakhama, Abdelfatteh
AU  - Zakhama A
FAU - Bergaoui, Naceur
AU  - Bergaoui N
LA  - eng
PT  - Journal Article
DEP - 20090321
PL  - France
TA  - Joint Bone Spine
JT  - Joint bone spine
JID - 100938016
RN  - 0 (Amyloid)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Abdominal Fat/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amyloid/metabolism
MH  - Amyloidosis/*epidemiology/pathology/physiopathology
MH  - Arthritis, Rheumatoid/*epidemiology/pathology/physiopathology
MH  - Biomarkers/metabolism
MH  - Biopsy, Needle
MH  - Comorbidity
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Salivary Glands, Minor/metabolism/pathology
MH  - Severity of Illness Index
MH  - Tunisia/epidemiology
MH  - Young Adult
EDAT- 2009/03/24 09:00
MHDA- 2009/07/17 09:00
CRDT- 2009/03/24 09:00
PHST- 2008/08/21 00:00 [accepted]
PHST- 2009/03/24 09:00 [entrez]
PHST- 2009/03/24 09:00 [pubmed]
PHST- 2009/07/17 09:00 [medline]
AID - S1297-319X(09)00011-6 [pii]
AID - 10.1016/j.jbspin.2008.08.009 [doi]
PST - ppublish
SO  - Joint Bone Spine. 2009 May;76(3):254-9. doi: 10.1016/j.jbspin.2008.08.009. Epub 
      2009 Mar 21.